You are here

kidney disease

Calliditas starts Phase II trial for rare kidney disease therapy

Calliditas starts Phase II trial for rare kidney disease therapy

Clinical Trials Arena

Calliditas Therapeutics

clinical trials

Alport syndrome

Flag link:

Travere Touts Phase III Kidney Disease Data for Filspari After Trial Failures

Travere Touts Phase III Kidney Disease Data for Filspari After Trial Failures

BioSpace

Travere Therapeutics

clinical trials

Flag link:

As trial miss threatens FDA approval, Travere points to Filspari's benefits in bid to stay in kidney disease

As trial miss threatens FDA approval, Travere points to Filspari's benefits in bid to stay in kidney disease

Fierce Pharma

Travere Therapeutics

IgA nephropathy

Flag link:

Omeros terminates kidney disease trial as therapy fails in late-stage study

Omeros terminates kidney disease trial as therapy fails in late-stage study

Reuters

clinical trials

Berger's disease

Flag link:

AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million

AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million

Forbes

Flag link:

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Clinical Trials Arena

clinical trials

IgA nephropathy

Flag link:

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

BioSpace

Travere Therapeutics

clinical trials

Flag link:

ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect

ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect

Fierce Pharma

drug manufacturing

Flag link:

Novartis to acquire kidney disease biotech Chinook for up to $3.5B

Novartis to acquire kidney disease biotech Chinook for up to $3.5B

BioPharma Dive

Chinook Therapeutics

Flag link:

HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions

HI-Bio's expectations elevated after pair of phase 2 readouts bolster autoimmune ambitions

Fierce Biotech

Human Immunology Bioscience

Flag link:

Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments

Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments

Fierce Biotech

Flag link:

As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

Endpoints

Ionis Pharmaceuticals

Flag link:

Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease

Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease

MedCity News

Human Immunology Bioscience

autoimmune disease

Flag link:

Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug

Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug

Fierce Biotech

Flag link:

FDA’s liver safety request set to delay decision on Travere’s kidney drug

FDA’s liver safety request set to delay decision on Travere’s kidney drug

Fierce Biotech

Travere Therapeutics

Flag link:

Regulus reports positive findings from Phase I kidney disease trial

Regulus reports positive findings from Phase I kidney disease trial

Clinical Trials Arena

clinical trials

Flag link:

Where Will Vertex Pharmaceuticals Be in 1 Year?

Where Will Vertex Pharmaceuticals Be in 1 Year?

Motley Fool

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment

Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment

Fierce Biotech

chronic kidney disease

Flag link:

Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again

Travere fails to convince regulators to consider accelerated approval for a rare kidney disease — again

Endpoints

Travere Therapeutics

Flag link:

Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant

Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant

Fierce Biotech

Ionis Pharmaceuticals

clinical trials

Flag link:

Pages